SYNERGIC PHARMACEUTICAL COMPOSITION, USEFUL FOR INHIBITING CORNEAL AND RETINAL NEOVASCULARIZATION (ANGIOGENESIS), AND IN OTHER ORGANS, IN A HUMAN BEING OR ANIMAL
A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof and 40 to 10 weight % Bevacizumab wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
